Skip to main content

Table 1 Characteristics and outcomes among different groups

From: Management of enterococcal central line-associated bloodstream infections in patients with cancer

Variables CLABSI with MBI (G1) CRBSI and CLABSI without MBI (G2) Non-CLABSI (G3) P-value Pairwise comparisons with significant differences
(n = 132) (n = 101) (n = 164)   
N (%) N (%) N (%)   
Age (years), median (range) 58 (19–89) 57 (10–87) 58 (18–82) 0.95  
Sex, male 90 (68) 64 (63) 91 (55) 0.08  
Type of cancer     < .0001 G1 vs G2:P < .0001; G1 vs G3: P < .0001
 Hematologic malignancy a 130 (98) 80 (79) 117 (71)   
 Solid tumor 2 (2) 21 (21) 47 (29)   
Transplant 49 (37) 45 (45) 37/163 (23) <.001 G1 vs G3: P = 0.007; G2 vs G3: P < .001
 Allogenienc 46/49 (94) 42/45 (93) 33/37 (89)   
 Autologous 3/49 (6) 3/45 (7) 4/37 (11)   
Neutropenia (ANC < 500 cells/microL) 127 (96) 15 (15) 85 (52) < .0001 G1 vs G2: P < .0001; G1 vs G3: P < .0001; G2 vs G3: P < .0001
Admission to the Intensive Care Unit at bacteremia onset 27 (20) 26 (26) 28 (17) 0.24  
Graft versus host disease at bacteremia onset 6/131 (5) 6 (6) 10/159 (6) 0.81  
Colonization with Vancomycin Resistant Enterococci (VRE) at bacteremia onset 48/122 (39) 21/80 (26) 42/124 (34) 0.16  
Enterococcus species
E. faecalis 41 (31) 63 (62) 75 (46) < .0001 G1 vs G2; P < .0001; G1 vs G3: P = .01; G2 vs G3: P = .01
E. faecium 85 (64) 37 (37) 78 (48) < .0001 G1 vs G2: P < .0001; G1 vs G3: P = .004
 Other Enterococcus species b 6 (5) 1 (1) 11 (7) 0.09  
VRE isolate 56/131 (43) 29/100 (29) 48 (29) 0.027 G1 vs G3: P = .016;
Days between cvc insertion and positive culture, median (IQR) 30 (16–91) 61 (17–125) 55 (21–177) 0.007 G1 vs G3: P = .002
Catheter management     0.004 G2 vs G3: P < .001
 Removal 64 (48) 56 (55) 59 (36)   
 Lock therapy 2 (2) 3 (3) 1 (1)   
 Catheter retained (without lock therapy) 66 (50) 42 (42) 104 (63)   
Catheter removal since positive blood culture c     0.008 G2 vs G3: P = .003
 <  3 days 29/130 (22) 32/98 (33) 32/163 (20)   
 3–7 days 31/130 (24) 22/98 (22) 23/163 (14)   
 >  7 days (including catheter retained) 70/130 (54) 44/98 (45) 108/163 (66)   
Received Antibiotics 125 (95) 96 (95) 149 (91) 0.30  
Duration of antibiotic therapy (days), median (IQR) 16 (11–22) 15 (9–18) 15 (10–22) 0.53  
Complications within 3 months 7/130 (5) 8/98 (8) 6/155 (4) 0.34  
All-cause mortality within 3 months 67 (51) 39 (39) 71 (43) 0.17  
Infection-related mortality within 3 months 16/131 (12) 8/97 (8) 13/158 (8) 0.45  
Recurrence within 3 months since microbiologic resolution d 10/111 (9) 6/88 (7) 11/137 (8) 0.85  
  1. Abbreviations: CLABSI central line-associated bloodstream infection, MBI mucosal barrier injury, CVC central venous catheter, VRE vancomycin resistant enterococcus
  2. a Six patients with hematologic malignancy had solid tumor as well
  3. b Included E. Gallinarum, E. Casseliflavus and other Enterococcus spp. unidetified
  4. c Patients with lock therapy were excluded from the analysis
  5. d Patients without mocrobiological resolution and patients whose recurrence data were unkown were excluded in the analysis